A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report

20260 citationsJournal Articlegold Open Access

Authors

Tinashe Mazhindu · University of Zimbabwe

Zedias Chikwambi · African Institute of Biomedical Science and Technology

Edith Matsikidze · University of Zimbabwe

Kevin Grimes · Stanford University

Margaret Borok · University of Zimbabwe

Ntokozo Ndlovu · University of Zimbabwe

Collen Masimirembwa

Abstract

This case shows that the severe adverse effects of capecitabine therapy in a patient with a CDA ultrametabolizer profile can be successfully switched to 5-FU-based therapy at a normal dose and tolerate this alternative fluoropyrimidine.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Genetic factors in colorectal cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Management and Research

Volume Volume 18, pp. 1-8

DOI: 10.2147/cmar.s571794

Field-Weighted Citation Impact: 0.00